Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients

Cancer Science

Volumn 107, Issue 6, 2016, Pages 755-763

  Tamura, Kenji ^a,b   Mukai, Hirofumi ^c   Naito, Yoichi ^a,c   Yonemori, Kan ^b   Kodaira, Makoto ^b   Tanabe, Yuko ^a   Yamamoto, Noboru ^a,b   Osera, Shozo ^c   Sasaki, Masaoki ^c   Mori, Yuko ^d   Hashigaki, Satoshi ^d   Nagasawa, Takashi ^d   Umeyama, Yoshiko ^d   Yoshino, Takayuki ^c  

^a NATIONAL CANCER CENTER   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d PFIZER INC   (United States)

Author keywords

Breast cancer; cyclin dependent kinase; Japanese; letrozole; palbociclib

Indexed keywords

LETROZOLE; PALBOCICLIB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS CANCER; FATIGUE; FEMALE; HUMAN; JAPANESE (PEOPLE); MALE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RECTUM CANCER; SIDE EFFECT; SOLID TUMOR; TREATMENT RESPONSE;

EID: 84979084000     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12932     Document Type: Article

References (11)

1. Fry DW, Harvey PJ, Keller PR et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004; 3: 1427–38.
2. Toogood PL, Harvey PJ, Repine JT et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem 2005; 48: 2388–406.
3. Marzec M, Kasprzycka M, Lai R et al. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood 2006; 108: 1744–50.
4. Saab R, Bills JL, Miceli AP et al. Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells. Mol Cancer Ther 2006; 5: 1299–308.
5. Roberts PJ, Bisi JE, Strum JC et al. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst 2012; 104: 476–87.
6. Finn RS, Dering J, Conklin D et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009; 11: R77.
7. Milani A, Geuna E, Mittica G, Valabrega G. Overcoming endocrine resistance in metastatic breast cancer: current evidence and future directions. World J Clin Oncol 2014; 5: 990–1001.
8. Finn RS, Crown JP, Lang I et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015; 16: 25–35.
9. Flaherty KT, Lorusso PM, Demichele A et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res 2012; 18: 568–76.
10. Sun W, Wang DD. A population pharmacokinetic (PK) analysis of palbociclib (PD-0332991) in patients (pts) with advanced solid tumors [abstract 462P]. Ann Oncol 2014; 25: iv146–64.
11. Turner NC, Ro J, Andre F et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 2015; 373: 209–19.